Cargando…

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer

Poly(ADP-ribose) polymerase inhibitors (PARPis) induce DNA lesions that preferentially kill homologous recombination (HR)-deficient breast cancers induced by BRCA mutations, which exhibit a low incidence in breast cancer, thereby limiting the benefits of PARPis. Additionally, breast cancer cells, pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Ying, Liu, Zhixian, Gui, Liang, Yun, Wen, Mao, Changfei, Deng, Rong, Yao, Yufeng, Yu, Qiao, Feng, Jifeng, Ma, Hongxia, Bao, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10167262/ https://www.ncbi.nlm.nih.gov/pubmed/37156759 http://dx.doi.org/10.1038/s41523-023-00540-3

Ejemplares similares

Novel clinical and genetic insight into CXorf56-associated intellectual disability
por: Rocha, Maria Eugenia, et al.
Publicado: (2019)

CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
por: Paret, Claudia, et al.
Publicado: (2015)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

MAMLD1 (CXorf6) is a New Gene for Hypospadias
por: Ogata, Tsutomu, et al.
Publicado: (2008)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

The Role of the Reanalysis of Genetic Test Results in the Diagnosis of Dysmorphic Syndrome Caused by Inherited Xq24 Deletion including the UBE2A and CXorf56 Genes
por: Wolańska, Ewelina, et al.
Publicado: (2021)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

A Fragment of Apolipoprotein E4 Leads to the Downregulation of a CXorf56 Homologue, a Novel ER-Associated Protein, and Activation of BV2 Microglial Cells
por: Pollock, Tanner B., et al.
Publicado: (2019)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients
por: Matsushita, M, et al.
Publicado: (2017)

Characterization of cxorf21 Provides Molecular Insight Into Female-Bias Immune Response in SLE Pathogenesis
por: Harris, Valerie M., et al.
Publicado: (2019)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing CXorf21
por: Harris, Valerie M., et al.
Publicado: (2019)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2022)

Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in Systemic Lupus Erythematosus
por: Odhams, Christopher A., et al.
Publicado: (2019)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
por: Boerner, Julie L., et al.
Publicado: (2015)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
por: Zeng, Xiaoqi, et al.
Publicado: (2021)

Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells
por: Moustafa, Dina, et al.
Publicado: (2021)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

Backbone and nearly complete side-chain chemical shift assignments reveal the human uncharacterized protein CXorf51A as intrinsically disordered
por: Wiedemann, Christoph, et al.
Publicado: (2021)

PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
por: Song, Wei, et al.
Publicado: (2017)

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
por: Bustos, Matias A., et al.
Publicado: (2023)

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
por: Liu, Zhixian, et al.
Publicado: (2018)

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
por: Nowsheen, Somaira, et al.
Publicado: (2012)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vfdkgmi8716e4vsi82r44c3199